Trials / Unknown
UnknownNCT01676558
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
A Phase II Study of 131I-rituximab for Elderly or Poor Performance Status Patients With Diffuse Large B Cell Lymphoma (DLBCL) or for Adult Patients With Relapsed or Refractory DLBCL
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Korea Cancer Center Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in Korea. Although there is standard therapy, which is called 'R-CHOP', many obstacles to use aggressive cytotoxic chemotherapeutic agents such as old age, poor performance status, refractoriness, and relapsed disease still remains. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with DLBCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 131I-rituximab |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2016-06-01
- Completion
- 2017-06-01
- First posted
- 2012-08-31
- Last updated
- 2012-11-14
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01676558. Inclusion in this directory is not an endorsement.